Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GT Biopharma, Inc. - Common Stock (NQ:GTBP)

7.210 +0.320 (+4.64%)
Streaming Delayed Price Updated: 12:27 PM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GT Biopharma, Inc. - Common Stock

News headline image
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
From Equity Insider
Via GlobeNewswire
News headline image
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
From Biotech Insider
Via GlobeNewswire
News headline image
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
From World Street Intelligence
Via GlobeNewswire
News headline image
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
From USA News Group
Via GlobeNewswire
News headline image
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Replays from RedChip's Biotech Investor Conference Now Available
Via ACCESS Newswire
News headline image
RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation
Via ACCESS Newswire
News headline image
THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle
Issued on behalf of Ventripoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Issued on behalf of GT Biopharma, Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
Issued on behalf of Ventripoint Diagnostics Ltd. 
From USA News Group
Via GlobeNewswire
News headline image
THE REALITY CHECK: 5 Assets Delivering Proof in a Speculative Market
From Equity Insider
Via GlobeNewswire
News headline image
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
Via ACCESS Newswire
News headline image
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:LPTX),(NASDAQ:IOBT),(NASDAQ:CELC),(NYSE:MAIA) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer
From GT Biopharma, Inc.
Via GlobeNewswire
News headline image
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
From GT Biopharma, Inc.
Via GlobeNewswire
News headline image
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From GT Biopharma, Inc.
Via GlobeNewswire
News headline image
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting
From GT Biopharma, Inc.
Via GlobeNewswire
News headline image
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update
From GT Biopharma, Inc.
Via GlobeNewswire
News headline image
GT Biopharma Announces Adjournment of Special Shareholders Meeting
From GT Biopharma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.